Literature DB >> 15871085

[Teleradiology with DICOM e-mail: recommendations of @GIT].

P Mildenberger1, M Kämmerer, U Engelmann, S Ruggiero, G Klos, A Runa, A Schröter, G Weisser, M Walz, B Schütze.   

Abstract

E-mail is ideal for ad-hoc connections in teleradiology. The DICOM standard offers the possibility to append DICOM data types as a MIME attachment to any e-mail, thus ensuring the transmission of the original DICOM data. Nevertheless, there are additional requirements (e.g. protection of data privacy) which must be obeyed. Because of the lack of given standards which would grant interoperability as well as manufacturer independence, teleradiology has not been established in Germany until today. Therefore, the IT-Team (Arbeitsgemeinschaft fur Informationstechnologie, @GIT) of the Radiological Society of Germany (Deutsche Rontgengesellschaft, DRG) set up an initiative to standardise telemedicine by using e-mail. Its members agreed that an e-mail-based variant would be the most practicable way to a communication solution -- as easy to implement as to use. In their opinion, e-mail represents the smallest common denominator for a safe data interchange that would fulfill the legal advantages for telemedicine in Germany.

Mesh:

Year:  2005        PMID: 15871085     DOI: 10.1055/s-2005-858049

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  3 in total

1.  Standardization of teleradiology using Dicom e-mail: recommendations of the German Radiology Society.

Authors:  G Weisser; M Walz; S Ruggiero; M Kämmerer; A Schröter; A Runa; P Mildenberger; U Engelmann
Journal:  Eur Radiol       Date:  2005-10-15       Impact factor: 5.315

Review 2.  [Current developments in DICOM and IHE].

Authors:  P Mildenberger; B Wein; H-P Bursig; M Eichelberg
Journal:  Radiologe       Date:  2005-08       Impact factor: 0.635

3.  Teleradiology applications with DICOM-e-mail.

Authors:  G Weisser; U Engelmann; S Ruggiero; A Runa; A Schröter; S Baur; M Walz
Journal:  Eur Radiol       Date:  2006-10-10       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.